- Home
- UDMY vs GHRS Comparison
UDMY vs GHRS Comparison
Compare UDMY & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UDMY
- GHRS
- Stock Information
- Founded
- UDMY 2009
- GHRS 2018
- Country
- UDMY United States
- GHRS Ireland
- Employees
- UDMY N/A
- GHRS N/A
- Industry
- UDMY Other Consumer Services
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- UDMY Real Estate
- GHRS Health Care
- Exchange
- UDMY Nasdaq
- GHRS Nasdaq
- Market Cap
- UDMY 1.1B
- GHRS 960.2M
- IPO Year
- UDMY 2021
- GHRS 2021
- Fundamental
- Price
- UDMY $7.61
- GHRS $14.36
- Analyst Decision
- UDMY Buy
- GHRS Strong Buy
- Analyst Count
- UDMY 10
- GHRS 8
- Target Price
- UDMY $9.89
- GHRS $30.63
- AVG Volume (30 Days)
- UDMY 1.5M
- GHRS 352.7K
- Earning Date
- UDMY 07-30-2025
- GHRS 09-02-2025
- Dividend Yield
- UDMY N/A
- GHRS N/A
- EPS Growth
- UDMY N/A
- GHRS N/A
- EPS
- UDMY N/A
- GHRS N/A
- Revenue
- UDMY $795,538,000.00
- GHRS N/A
- Revenue This Year
- UDMY $2.02
- GHRS N/A
- Revenue Next Year
- UDMY $4.19
- GHRS N/A
- P/E Ratio
- UDMY N/A
- GHRS N/A
- Revenue Growth
- UDMY 3.93
- GHRS N/A
- 52 Week Low
- UDMY $5.68
- GHRS $6.00
- 52 Week High
- UDMY $10.61
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- UDMY 60.32
- GHRS 47.65
- Support Level
- UDMY $6.94
- GHRS $12.81
- Resistance Level
- UDMY $7.90
- GHRS $15.28
- Average True Range (ATR)
- UDMY 0.34
- GHRS 1.52
- MACD
- UDMY 0.05
- GHRS -0.40
- Stochastic Oscillator
- UDMY 70.00
- GHRS 23.13
About UDMY Udemy Inc.
Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Consumer and Enterprise, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.